JP2010526858A5 - - Google Patents

Info

Publication number

JP2010526858A5

JP2010526858A5 JP2010507939A JP2010507939A JP2010526858A5 JP 2010526858 A5 JP2010526858 A5 JP 2010526858A5 JP 2010507939 A JP2010507939 A JP 2010507939A JP 2010507939 A JP2010507939 A JP 2010507939A JP 2010526858 A5 JP2010526858 A5 JP 2010526858A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

composition according

active substance

day

release

Prior art date

2008-05-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Withdrawn

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims 16
• 239000013543 active substance Substances 0.000 claims 12
• HZCBWYNLGPIQRK-LBPRGKRZSA-N 3,3',5'-triiodo-L-thyronine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC=C1OC1=CC(I)=C(O)C(I)=C1 HZCBWYNLGPIQRK-LBPRGKRZSA-N 0.000 claims 9
• CPCJBZABTUOGNM-UHFFFAOYSA-N 3',3-diiodothyronine Natural products IC1=CC(CC(N)C(O)=O)=CC=C1OC1=CC=C(O)C(I)=C1 CPCJBZABTUOGNM-UHFFFAOYSA-N 0.000 claims 4
• RUIUIJSMLKJUDC-ZDUSSCGKSA-N 3'-monoiodothyronine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C(I)=C1 RUIUIJSMLKJUDC-ZDUSSCGKSA-N 0.000 claims 4
• 229940088597 hormone Drugs 0.000 claims 4
• 239000005556 hormone Substances 0.000 claims 4
• 230000007170 pathology Effects 0.000 claims 4
• CPCJBZABTUOGNM-LBPRGKRZSA-N 3,3'-diiodo-L-thyronine Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C(I)=C1 CPCJBZABTUOGNM-LBPRGKRZSA-N 0.000 claims 3
• SXQVOFSDWXYIRP-ZDUSSCGKSA-N (2s)-2-azaniumyl-3-[4-(4-hydroxyphenoxy)-3-iodophenyl]propanoate Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC=C1OC1=CC=C(O)C=C1 SXQVOFSDWXYIRP-ZDUSSCGKSA-N 0.000 claims 2
• 208000032928 Dyslipidaemia Diseases 0.000 claims 2
• 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
• 206010033307 Overweight Diseases 0.000 claims 2
• 230000001476 alcoholic effect Effects 0.000 claims 2
• 206010012601 diabetes mellitus Diseases 0.000 claims 2
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
• 239000002243 precursor Substances 0.000 claims 2
• 238000002560 therapeutic procedure Methods 0.000 claims 2
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
• 201000001320 Atherosclerosis Diseases 0.000 claims 1
• 208000035484 Cellulite Diseases 0.000 claims 1
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
• 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
• 102000004877 Insulin Human genes 0.000 claims 1
• 108090001061 Insulin Proteins 0.000 claims 1
• 206010022489 Insulin Resistance Diseases 0.000 claims 1
• 208000008589 Obesity Diseases 0.000 claims 1
• 206010049752 Peau d'orange Diseases 0.000 claims 1
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
• 230000015572 biosynthetic process Effects 0.000 claims 1
• 230000036232 cellulite Effects 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
• 235000012000 cholesterol Nutrition 0.000 claims 1
• 230000007812 deficiency Effects 0.000 claims 1
• 230000008021 deposition Effects 0.000 claims 1
• 239000003085 diluting agent Substances 0.000 claims 1
• 239000008393 encapsulating agent Substances 0.000 claims 1
• 239000000945 filler Substances 0.000 claims 1
• 208000020694 gallbladder disease Diseases 0.000 claims 1
• 239000008103 glucose Substances 0.000 claims 1
• 230000002440 hepatic effect Effects 0.000 claims 1
• 201000001421 hyperglycemia Diseases 0.000 claims 1
• 208000006575 hypertriglyceridemia Diseases 0.000 claims 1
• 230000001939 inductive effect Effects 0.000 claims 1
• 229940125396 insulin Drugs 0.000 claims 1
• 238000007918 intramuscular administration Methods 0.000 claims 1
• 238000007912 intraperitoneal administration Methods 0.000 claims 1
• 238000001990 intravenous administration Methods 0.000 claims 1
• 239000007788 liquid Substances 0.000 claims 1
• 208000030159 metabolic disease Diseases 0.000 claims 1
• 235000020824 obesity Nutrition 0.000 claims 1
• 230000036470 plasma concentration Effects 0.000 claims 1
• 210000002374 sebum Anatomy 0.000 claims 1
• 230000028327 secretion Effects 0.000 claims 1
• 239000007787 solid Substances 0.000 claims 1
• 238000007920 subcutaneous administration Methods 0.000 claims 1
• 210000004003 subcutaneous fat Anatomy 0.000 claims 1
• 150000003626 triacylglycerols Chemical class 0.000 claims 1
• 208000001319 vasomotor rhinitis Diseases 0.000 claims 1